- Trials with a EudraCT protocol (55)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
55 result(s) found for: Abl Gene.
Displaying page 1 of 3.
EudraCT Number: 2005-001294-99 | Sponsor Protocol Number: CA180-034 | Start Date*: 2005-07-18 |
Sponsor Name:Bristol-Myers Squibb International Corporation | ||
Full Title: A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Ph... | ||
Medical condition: Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia who are resistant or intolerant to Imatinib Mesylate | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) SE (Completed) GB (Completed) HU (Completed) DK (Completed) IE (Completed) CZ (Completed) FI (Completed) IT (Completed) EE (Completed) ES (Completed) DE (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-004252-37 | Sponsor Protocol Number: IPH1101-204 | Start Date*: 2007-10-11 | |||||||||||
Sponsor Name:Innate Pharma | |||||||||||||
Full Title: A Phase I/II open label study to assess efficacy and safety of IPH1101 associated with low dose of interleukin 2, as add-on therapy to imatinib in CML patients with residual molecular disease | |||||||||||||
Medical condition: Chronic Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017340-14 | Sponsor Protocol Number: RHMCAN0700 | Start Date*: 2011-07-26 |
Sponsor Name:University Hospital Southampton NHS Foundation Trust | ||
Full Title: WT1 Immunity via DNA fusion Gene Vaccination in Haematological Malignancies by intramuscular injection followed by intramuscular electroporation. | ||
Medical condition: Chronic myeloid Leukemia and acute myeloid leukemia in cytogentic remission | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2010-018339-16 | Sponsor Protocol Number: CSTI571ADE75T-GMIHO-005/2009 | Start Date*: 2010-07-19 | |||||||||||
Sponsor Name:GMIHO mbH | |||||||||||||
Full Title: CRESCENDO (Compliance: Role Emerges for Success in CML: Evaluation aND Optimisation): A prospective, multi-center, phase IV study to assess the compliance in patients with Philadelphia chromosome-p... | |||||||||||||
Medical condition: CML - chronic myelogenous leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000077-68 | Sponsor Protocol Number: CAMN107ADE18T | Start Date*: 2013-12-10 | ||||||||||||||||
Sponsor Name:Medical Center - University of Freiburg | ||||||||||||||||||
Full Title: Imatinib continuation versus Nilotinib 300 mg twice daily in patients with chronic myeloid leukemia (CML) in chronic phase and major molecular response (MMR) without molecular response ≥ 4.5 log (M... | ||||||||||||||||||
Medical condition: chronic myeloid leukemia (CML) in 1st chronic phase and confirmed major molecular response (MMR) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-003502-16 | Sponsor Protocol Number: DasaHIT | Start Date*: 2016-08-11 | |||||||||||
Sponsor Name:Friedrich-Schiller-Universität Jena | |||||||||||||
Full Title: Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment naïve disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase Inhibitors... | |||||||||||||
Medical condition: Chronic Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000208-34 | Sponsor Protocol Number: CAMN107A2303 | Start Date*: 2007-06-11 | ||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
Full Title: A phase III multi-center, open label, randomised study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chr... | ||||||||||||||||||
Medical condition: Adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) CZ (Completed) BE (Completed) IT (Completed) ES (Completed) SK (Completed) AT (Completed) FR (Completed) NL (Completed) FI (Completed) DK (Completed) DE (Completed) PT (Prematurely Ended) HU (Completed) GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-000176-32 | Sponsor Protocol Number: CGX-635-CML-202 | Start Date*: 2006-09-22 |
Sponsor Name:Stragen France | ||
Full Title: A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (Omacetaxine) (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL G... | ||
Medical condition: Chronic Myeloid Leukaemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) GB (Completed) HU (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-001169-32 | Sponsor Protocol Number: CA180-035 | Start Date*: 2005-11-16 |
Sponsor Name:Bristol-Myers Squibb International Corporation | ||
Full Title: A Randomized Two-Arm, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects with Chronic Myeloid Leukemia in Acce... | ||
Medical condition: Subjects with Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) or in Myeloid (My) or Lymphoid (Ly) Blast Phase (BP) or with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) SE (Completed) HU (Completed) DK (Completed) IE (Completed) CZ (Completed) FI (Completed) ES (Completed) IT (Completed) BE (Completed) DE (Completed) AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001805-34 | Sponsor Protocol Number: CSTI571I1203 | Start Date*: 2017-08-15 |
Sponsor Name:Novartis Pharma K.K | ||
Full Title: Phase II Study of Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia | ||
Medical condition: Philadelphia Chromosome Positive Acute Lymphocytic Leukemia (Ph+ALL) | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2012-004321-25 | Sponsor Protocol Number: NordDutchCML009 | Start Date*: 2013-04-03 | |||||||||||
Sponsor Name:VU University Medical Center | |||||||||||||
Full Title: A phase II, single arm, multicenter study of nilotinib in combination with pegylated interferon α2b in patients with suboptimal molecular response or stable detectable molecular residual disease af... | |||||||||||||
Medical condition: Chronic myeloid leukemia in chronic phase and ≥ 2 years on Imatinib treatment with suboptimal molecular response (BCR-ABL level above 0.01% IS). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) SE (Completed) NO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001483-51 | Sponsor Protocol Number: CAMN107A2101 | Start Date*: 2005-07-12 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec (imatinib)-resistant/intolerant CML in chronic or accelerated ph... | |||||||||||||
Medical condition: CML in chronic phase, accelerated phase or blast crisis, relapsed/refractory Ph+ ALL, systemic mastocytosis, or hypereosinophilic syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) GB (Completed) SE (Completed) IT (Completed) DK (Completed) AT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004384-19 | Sponsor Protocol Number: GIMEMA CML0408 | Start Date*: 2008-07-29 | |||||||||||
Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO | |||||||||||||
Full Title: Front-line treatment of Philadelphia positive (Ph pos), BCR-ABL positive, chronic myeloid leukemia (CML) with two tyrosine kinase inhibitors (TKI) (Nilotinib and Imatinib). A phase II exploratory m... | |||||||||||||
Medical condition: Philadelphia positive (Ph pos), BCR-ABL positive, Chronic Myeloid Leukemia (CML) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-013271-22 | Sponsor Protocol Number: GIMEMA LAL1408 | Start Date*: 2009-11-09 | |||||||||||
Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL`ADULTO | |||||||||||||
Full Title: Front-line treatment of Ph positive (Ph+)/Bcr-Abl positive Acute Lymphoblastic Leukemia (ALL) with two tyrosine kinase inhibitors (TKI) (Imatinib and Nilotinib). A phase II exploratory multicentr... | |||||||||||||
Medical condition: Ph positive (Ph+)/Bcr-Abl positive Acute Lymphoblastic Leukemia (ALL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024262-22 | Sponsor Protocol Number: CML-V | Start Date*: 2012-08-24 | |||||||||||
Sponsor Name:Friedrich-Schiller-Universität Jena | |||||||||||||
Full Title: Treatment optimization of newly diagnosed Ph/BCR-ABL positive patients with chronic myeloid leukemia (CML) in chronic phase with nilotinib vs. nilotinib plus interferon alpha induction and nilotini... | |||||||||||||
Medical condition: chronic phase CML | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002516-28 | Sponsor Protocol Number: CA180-006 | Start Date*: 2004-12-27 |
Sponsor Name:Bristol Myers Squibb International Corporation | ||
Full Title: A Phase II Study of BMS-354825 in Subjects with Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate Revised Protocol 01: Incorporates Amendment 03 and Admi... | ||
Medical condition: Myeloid Blast Phase Chronic Myeloid Leukemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) AT (Completed) FI (Completed) GB (Completed) DK (Completed) IT (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000705-20 | Sponsor Protocol Number: EsPhALL2017/COGAALL1631 | Start Date*: 2017-12-11 | ||||||||||||||||
Sponsor Name:Università degli Studi Milano Bicocca | ||||||||||||||||||
Full Title: International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones | ||||||||||||||||||
Medical condition: Philadelphia positive Acute Lumphoblastic Leukemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Ongoing) IT (Ongoing) NL (Ongoing) CZ (Ongoing) DE (Ongoing) FI (Ongoing) BE (Ongoing) SE (Ongoing) PL (Ongoing) DK (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001843-29 | Sponsor Protocol Number: TASTER2018 | Start Date*: 2019-05-28 | |||||||||||
Sponsor Name:NHS Greater Glasgow and Clyde [...] | |||||||||||||
Full Title: TASTER- TArgeting STEm cell Resistance An umbrella adaptive randomised multi–arm screening phase II trial for patients with 2nd/3rd generation TKI resistant chronic myeloid leukaemia | |||||||||||||
Medical condition: Chronic myeloid leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002882-35 | Sponsor Protocol Number: CA180-018 | Start Date*: 2006-03-02 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: Phase I study of Src/Abl tyrosine kinase inhibitor dasatinib [BMS-354825] in children and adolescents with relapsed or refractory leukemia, Protocol ITCC 005. Decision number of Paediatric Inves... | |||||||||||||
Medical condition: Children and adolescents with CML in chronic, accelerated or blast phase who are resistant or intolerant to imatinib, or in first or subsequent relapse of Ph+ ALL after prior imatinib, or in second... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) GB (Completed) IT (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014373-41 | Sponsor Protocol Number: H135 | Start Date*: 2010-02-12 | |||||||||||
Sponsor Name:NHS Greater Glasgow and Clyde | |||||||||||||
Full Title: A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and Imatinib (IM) for patients with Chronic Myeloid Leukaemia (CML) in Cytogenetic Response (CyR) with residual disease ... | |||||||||||||
Medical condition: Chronic Myeloid Leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.